Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 19c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($1.31), $0.19 worse than the analyst estimate of ($1.12).

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• EQT And KKKR Said Among Firms Considering Bids For Qiagen - Bloomberg
• Sustainability 101: Materials at the Center of Sustainability, Human Rights, and Business Resilience
• Qiagen names Jonathan Pratt as CEO, replacing Thierry Bernard